Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, feasibility and cost-analysis of UGT1A1 genotype-guided dosing of irinotecan
2016-004576-22Phase 4Active
- Sponsor
- Catharina Ziekenhuis
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of irinotecan in cancer, sponsored by Catharina Ziekenhuis. Primary endpoint: Incidence of febrile neutropenia during first two cycles. Started May 2017; status: active.
02
Drugs
irinotecan
03
Conditions
cancer
Beyond the preview
Go deeper on 2016-004576-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004576-22.